Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Terminated
Western Regional Medical Center
Phase 2
2013-02-01
To determine whether the occurrence of adverse events can be decreased by moving to a
bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of
unresectable/metastatic pancreatic cancer.
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Completed
Celgene
Phase 1
2015-01-12
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens
administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small
Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Completed
Celgene Corporation
Phase 1
2015-01-12
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens
administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small
Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
